Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company focused on developing briquilimab, an aglycosylated monoclonal antibody targeting KIT (CD117) for chronic mast cell diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma. The JSPR news feed highlights company announcements on clinical data, corporate developments and financing activities that shape the outlook for this mast cell–focused program.
News updates commonly cover clinical trial results and study updates. Jasper has reported data from the BEACON Phase 1b/2a study in CSU, an open-label extension study in chronic urticarias, and the ETESIAN Phase 1b/2a study in allergic asthma. These releases describe endpoints such as Urticaria Activity Score over 7 days (UAS7), hives and itch severity scores, airway hyperresponsiveness, sputum eosinophils, serum tryptase, and safety findings, including observations related to KIT blockade.
The JSPR news stream also includes corporate and strategic announcements, such as leadership changes, corporate reorganizations, and decisions to concentrate resources on briquilimab in mast cell driven diseases. Investors can find information on Jasper’s participation in healthcare and investor conferences, where management discusses briquilimab’s development and provides program updates.
In addition, Jasper issues financing and capital markets news, including details of public offerings of common stock, pre-funded warrants and common warrants, and stated uses of proceeds for advancing briquilimab and supporting general corporate purposes. Together, these news items provide context on clinical progress, strategic focus and funding for Jasper’s lead program. For readers tracking JSPR, this page offers a centralized view of the company’s press releases and related communications.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) announced the initiation of a Phase 1b/2a study evaluating briquilimab in asthma patients in Q4 2024. Briquilimab targets mast cell-driven diseases like chronic spontaneous urticaria and chronic inducible urticaria. The company presented promising preclinical data at the recent AAAAI annual meeting, demonstrating the depletion of mast cells in the airways and prevention of allergen-induced asthmatic responses. Jasper plans to host a KOL webinar on May 20, 2024, featuring Professor Joshua Boyce to discuss the potential of briquilimab in asthma.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) will present at upcoming investor conferences in May to discuss the development of briquilimab, a novel antibody therapy addressing mast cell driven diseases. The company's management will participate in panel discussions at Capital One Securities Biotech/Biopharma Disruptors Event and in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.